Blue Jet Healthcare reported a net profit of ₹782.64 million for the quarter ended June 30, 2026 (Q1FY27), marking a 14.2% year-on-year decline from ₹911.70 million in the corresponding period of FY26. The contraction followed a 15.1% drop in total income from operations to ₹3,083.50 million from ₹3,630.12 million. Despite the top-line headwind, the company maintained robust profitability through disciplined cost management, with operating EBITDA margins expanding to 33.5% from 30.4% in the previous quarter. On August 3, 2026, the Board of Directors approved the unaudited standalone financial results and declared an interim dividend of ₹1.2 per equity share, with September 14, 2026, set as the record date.

The financial performance reflects slight pressure on operating leverage, as total expenses decreased by only 15.7% to ₹2,024 million compared to the revenue decline. However, other income surged by 83.1% to ₹152 million from ₹83 million in Q1FY26, providing a meaningful offset to the operational dip. Tax expense for the quarter stood at ₹277 million. In a significant capital market move subsequent to the quarter end, Blue Jet Healthcare completed a Qualified Institutional Placement (QIP), allotting 15.8 million equity shares at ₹506 per share to raise ₹8,000 million. This infusion strengthens the balance sheet ahead of its planned capacity expansions.

Q1FY27 Financial Highlights

The following table outlines the key financial metrics for the quarter ended June 30, 2026, alongside comparative figures from the previous year:

Revenue from operations contributed significantly to the total income, which fell by ₹546.62 million year-on-year. Gross profit stood at ₹1,560 million, down 9.2% from ₹1,719 million in Q1FY26. Employee benefits expenses rose to ₹201 million from ₹174 million, reflecting investments in human capital, while other expenses decreased to ₹378 million from ₹334 million. Depreciation and amortization were recorded at ₹67 million, and finance costs remained stable at ₹7 million.

Operational Updates and Segment Performance

Management provided detailed insights into segment performance during the earnings call. Revenue from operations was reported at ₹2,930 million, showing a 25% sequential increase. The growth was primarily driven by the PI and API segments, where supply resumed after customer destocking in previous quarters. V.K. Singh, Chief Operating Officer, stated that there is clear secular growth in the formulation market for these products, with a strong order book providing visibility for the next three to four quarters.

In contrast, the Contrast Media segment saw a decline due to transit delays caused by container unavailability and geopolitical factors. Ganesh Karuppannan, Chief Financial Officer, noted that goods in transit were higher by approximately ₹300 million compared to the opening balance, leading to lower recognized sales in this quarter. Plant utilization levels remained steady at over 70%, with production-to-dispatch rates at 100%. Raw material prices increased post-March due to geopolitical tensions, partially impacting gross margins, which contracted by 3% to 53%. Management indicated that price pass-through mechanisms are under evaluation on a case-by-case basis.

Capital Expenditure and Strategic Expansion

Blue Jet Healthcare outlined a significant investment programme, signaling commitment to long-term growth. The company expects to spend approximately ₹250 crore in capital expenditure for FY27 as part of a larger ₹1,000 crore plan over the next three years. Key projects include:

• Unit 3 (Mahad): Backward integration project for contrast media intermediates is ahead of schedule, with commercial contribution expected in H2FY27. Approximately ₹2,100 million has been invested so far, with an additional ₹400 million committed.
• Vizag Project: Phase 1 focuses on expanding contrast media manufacturing and establishing multipurpose finishing blocks. Engineering activities are progressing well, with commercialization expected from late FY29 to FY30.
• Hyderabad R&D Center: Expected to become operational in August 2026, focusing on peptides, GLP-1 intermediates, and biocatalysts.

The company plans to launch three candidates in the Contrast Media segment and initiate pilot activities for a new high-intensity sweetener in FY27. Additionally, two high-conviction opportunities in chronic therapy (oncology and CNS) are expected to fructify within the next two years.

What the Numbers Show

The divergence between revenue decline (-15.1%) and expense reduction (-15.7%) indicates slight pressure on operating leverage in Q1FY27. While top-line growth contracted, the company's ability to reduce costs nearly in line with revenue helped contain the net profit decline to 14.2%, which is less severe than the revenue drop. The significant rise in other income suggests non-operational gains contributed meaningfully to the bottom line. The approved dividend of ₹1.2 per share, combined with the ₹1,000 crore capex commitment over three years and a well-defined pipeline across chronic therapy, Contrast Media, and new product segments, reflects management's dual focus on rewarding shareholders while investing in long-term growth capacity. The recent ₹8,000 million QIP provides substantial liquidity to fund these expansion plans.

Blue Jet Healthcare Limited has made the audio recording of its quarterly earnings conference call publicly available, concluding its disclosure obligations for the first quarter of FY27. The call, held on Monday, August 3, 2026, at 5:30 PM IST, focused on the company’s unaudited standalone financial results for the quarter ended June 30, 2026. This update ensures stakeholders have direct access to management’s commentary on operational performance and financial health.

The company notified both BSE Limited and the National Stock Exchange of India Limited regarding the submission of the audio recording on August 3, 2026. This action complies with Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sweta Poddar, Company Secretary & Compliance Officer, signed off on the communication, confirming the recording is hosted on the company’s official investor relations portal.

Conference Call Access Details

Investors and analysts can access the full recording via the link provided on the company’s website. The original live event allowed participants to join via universal access numbers or international toll-free lines. Management representatives were available to address queries regarding the financial results and operational updates. Participants were advised to dial in 10 minutes before the scheduled start time to ensure timely entry.

Management Representation

The following executives represented Blue Jet Healthcare during the earnings discussion, providing insights into the company’s strategic direction and financial outcomes:

• Shiven Arora, Managing Director
• V.K. Singh, Chief Operating Officer
• Ganesh Karuppannan, Chief Financial Officer
• Sanjay Sinha, Deputy Chief Financial Officer

About Blue Jet Healthcare

Blue Jet Healthcare operates as a specialty pharmaceutical and healthcare ingredient company under a contract development and manufacturing organization (CDMO) business model. The firm specializes in contrast media intermediates and high-intensity sweeteners, serving global innovator and multinational generic pharmaceutical companies through multi-year contracts. Key clients include GE Healthcare, Guerbet, Bracco, Colgate Palmolive (India) Limited, and Unilever.